

# EUFEPS 2002

*All-in-one European Congress of Pharmaceutical  
Sciences & Exhibition*

## *Afternoon Specials*



*October 21-22 • 2002 • Stockholm • Sweden*

*Sponsored by the European Commission*



W  
W  
W  
W  
E  
U  
F  
E  
P  
S  
O  
R  
G

W  
W  
W  
W  
E  
U  
F  
E  
P  
S  
O  
R  
G



## **EUFEPS 2002 Parallel Afternoon Specials**

Over recent years, many small enterprises have been established. More of the discovery process and support to drug development seem to take place in small research units. Clinical development, scale-up and regulatory matters remain in the hands of bigger companies. Regulators approve all new medicines, for the European as well as the global market.

Whatever the setting, collaboration will be needed with a number of stakeholders, e.g. private and venture capital investors, training, education and health-care providers, national and other funding bodies, equipment suppliers etc. Also important are ethical considerations, patenting, job searching, start-up advice and so on.

In the EUFEPS 2002 Afternoon Specials, new and hot issues will be discussed and debated. Those having more experience will share with those having less experience. Register to the EUFEPS 2002, and enjoy the above programme. It was made possible by a generous grant from the European Commission.

## **Monday, October 21, 2002, at 5 pm**

### **EU 6<sup>th</sup> Framework Programme: Its basis and its pharmaceutical impact**

#### **Co-Chairs**

*Ole J Bjerrum and Alfredo Aguilar*

#### **Objectives**

The session is thought to convey an understanding of the thinking behind the programme in general and the pharmaceutical sciences in particular vis-à-vis the New Safe Medicines Faster initiative and Expressions of Interest the Commission have received.

#### **Format**

Lectures with discussion.

#### **Target Audience**

Potential applicants for grants under FP6.

#### **Programme**

- Drug discovery in the EU Framework Programme 6 (FP6)  
*Alfredo Aguilar*, Brussels BE
- New Safe Medicines Faster and FP6. New opportunities for the pharmaceutical sciences.  
*Ole J Bjerrum*, Copenhagen DK
- Results of the Expression of Interest with emphasis on those related to pharmaceuticals.  
*Thorbjörn Ingemansson*, Brussels BE
- Questions and Answers Panel

## Innovation and NCE development

### Co-Chairs

*Giovanni Gaviraghi* and *Jörgen Vessman*

### Objectives

This section is aimed to discuss from scientific, industrial and financial points of view the dramatic changes in the pharmaceutical drug discovery process which have taken place in the last decade.

### Format

Lectures with discussions

### Target Audience

Industrial and academic researchers and managers, financial experts

### Programme

- Overview of the changes in the discovery process in the 90's  
*Giovanni Gaviraghi*, Siena IT
- The productivity of the new drug discovery process within the industry: Challenges and perspectives  
*Robin Carr*, Cambridge UK
- Financial expectations from the new drug discovery paradigm  
*Erling Refsum*, London UK
- Panel Discussion, chaired by  
*Jörgen Vessman*, Mölndal SE

---

## Training and Education I

### Co-Chairs

*Bernd Clement* and *Fritz R. Bühler*

### Objectives

There is an increasing need in the pharmaceutical industry for academics who can cover broad areas of the total drug development process. There is strong support for pan-European post-graduate training programmes in pharmaceutical sciences to fill this gap. In two EUFEPS afternoon specials surveys on existing models and further initiatives will be presented and discussed.

### Format

Lectures with discussion

### Target Audience

Post-graduate students and all other involved in training and education

### Programme

- Postgraduate education for pharmaceutical scientists (EUFEPS' model and other)  
*Bernd Clement*, Kiel DE
- European pharmaceutical education – a new programme  
*Fritz R. Bühler*, Basel CH
- Postgraduate education of medicinal chemists (International Quality Network – Medicinal Chemistry and others)  
*TBA*
- Discussion

## Ethical aspects in drug development

### Chair

*Lars Reuter*

### Objectives

The development of new medical drugs takes place in an environment of diverse and often competing interests between consumers, producers, and lawmakers. Typically, freedom of research and the protection of the individual human being are seen as the two hallmarks guiding European policies on this development. This panel explores possibilities and problems in this regard.

### Format

Lectures with discussion

### Target Audience

R&D staff

### Programme

- Freedom of research and protection of the individual in a European perspective  
*Lars Reuter, Aarhus DK*
- Specific problems related to drug development  
*Ron Bergmans, Maastricht NL*
- Fundamental issues raised by drug development  
*Sven Andersen, Aarhus DK*
- Questions and Answers Panel

---

## Scientific east-west integration in Europe

### Co-Chairs

*Pia Vuorela and Sándor Görög*

### Objectives

New countries are entering EU and the activities to join e.g. the EU 6th Framework Programme are in full swing. The tools for successful integration of academia, research and pharmaceutical companies in a fast way needs to be evaluated. This Afternoon Special explores possibilities, problems and progress in this respect.

### Format

Lectures with panel discussion

### Target Audience

Potential persons for cooperation and networking

### Programme

- Research and development strategy in a recently privatised pharmaceutical company in Central/Eastern Europe  
*Gábor Blaskó, Budapest HU*
- Cooperation of universities in Central and Eastern European countries with western institutions  
*Alès Mrhar, Ljubljana SLO*
- What are the possibilities for the integration in Europe?  
*Peep Veski, Tartu EE*
- Panel discussion and written report

**Tuesday, October 22, 2002, at 4.45 pm**

**EU 6<sup>th</sup> Framework Programme: Specific instruments and measures.  
Practicalities and relevant examples**

**Co-Chairs**

*Alfredo Aguilar and Ole J Bjerrum*

**Objectives**

To convey an understanding of the intentions and contents of the new instruments, together with practical hints for the organisation of consortia and professional management. Many other funding possibilities of the FP6 for the pharmaceutical scientist will also be presented. The money allocated for training and education are doubled in FP6 for which reason examples for successful training programmes in large scale from FP5 are presented.

**Format**

Lectures with discussion.

**Target Audience**

Potential applicants for grants under FP6.

**Programme**

- New instruments for thematic priorities: Networks of Excellence, Integrated Projects and Stairways of Excellence, respectively.  
*Alfredo Aguilar*, Brussels BE
- Additional funding possibilities and practicalities: Specific targeted research and innovation projects, responsible research, specific research projects for SME's, training and education, co-operation frameworks, joint initiatives with scientific organisations, co-ordination actions, research infrastructures  
*Thorbjörn Ingemansson*, Brussels BE
- EU Training grants: Experience from FP5 on courses in big scale (> 1 mio Euro)  
*Heather Marshall-Heyman*, Stockholm SE
- Lesson to be learned from courses of the genetic basis of disease  
*Mikael Holst*, Stockholm SE
- Questions and Answers Panel

---

**Training and Education II**

**Co-Chairs**

*Bernd Clement and Fritz R. Bühler*

**Objectives**

There is an increasing need in the pharmaceutical industry for academics who can cover broad areas of the total drug development process. There is strong support for pan-European post-graduate training programmes in pharmaceutical sciences to fill this gap. In

two EUFEPS afternoon specials surveys on existing models and further initiatives will be presented and discussed.

**Format**

Lectures with discussion

**Target Audience**

Post-graduate students and all other involved in training and education

### **Programme**

- The “ULLA” Model  
*Birthe Jensen*, Copenhagen DK
- GALENOS Network and European post-graduate programme in advanced drug delivery  
*Claus-Michael Lehr*, Saarbrücken DE

- Drug Regulatory Affairs  
*Richard Süverkrüpp*, Bonn DE
- Discussion

---

## **How to promote innovation and and science driven regulation?**

### **Co-Chairs**

*André Broekmans* and *Maj-Inger Nilsson*

### **Format**

Lectures with discussion

### **Objectives**

At this moment the future medicines legislation is under debate in the European Parliament and in the Council. The proposals of the Commission will have important consequences for Research and Development within the European Union and the patient's access to innovative medicines. Do the proposals really foster the innovation in Europe and are decisions by the CPMP really science driven? The session will deliver new building blocks for the discussion.

### **Target Audience**

R&D staff, regulators and health care professionals

### **Programme**

- Perspective from the EMEA  
*Bo Aronsson*, London UK
- Perspective from a national authority  
*Gunnar Alvan*, Uppsala SE
- Perspective from academia  
*John Caldwell*, London UK
- Perspective from industry  
*George Butler*, Alderly Park UK
- General Discussion

---

## **Biotech innovations and SMEs do it smarter and faster**

### **Chair**

*Claes Post*

### **Objectives**

Drug discovery productivity has been defined as an area, where the large pharmaceutical companies has a problem. With this, the industry anticipates that the smaller innovation-driven companies will play an important role to fill the project gaps. Not to forget, however, a drug emanating from the

small companies needs to fulfil the same criteria as those generated from the larger companies in terms of data quality, and compliance with regulatory requirements. If a smarter approach is applied within the Biotech and SME's, it must therefore be combined with the same strict project criteria as those applied within the large companies. The overall objective of the session is to discuss approaches to drug discovery within the smaller research

companies, and how to match the requirements for quality and innovation. The session will also address the issue of interfacing start-up companies with the venture capital, academia and Contract Research Organisations (CRO's).

### **Format**

Lectures with discussion

### **Target Audience**

Scientists and managers from Biotech and SME's, scientists from academia and people from venture capital firms.

### **Programme**

- Introductory remarks  
*Claes Post*, Uppsala SE
- Innovation driven drug discovery and development  
*Björn Nilsson*, Stockholm SE
- The interface start-up companies and venture capital  
*Carl-Johan Dalsgaard*, Stockholm SE
- Academic-company interfaces and Contract Research Organisations (CRO)  
*Daan Crommelin*, Utrecht NL
- General Discussion

---

## **Pharma/public interface: “Dialogue with the public”**

### **Chair**

*Jens Degett*

### **Objectives**

Though we always hear how important it is to communicate science to the public many scientists are reluctant or even afraid of talking to the media about their research. This fear is not without reason, as there are many examples of how information has been misunderstood or misused by the press. Communication strategies and advice will be given on why and how to communicate with the public illustrated with examples from the real life.

### **Format**

Lectures, videoclip, discussion with the floor

### **Target Audience**

Scientists, science administrators, communicators.

### **Programme**

- Perils and prospects of communicating with the public
  1. The importance of communication
  2. Real life examples on good and bad communication
  3. Communication strategies how and why?
  4. General advice on communication, ethics and rules.*Jens Degett*, Strasburg FR and *Bo Øksnebjerg*, Bagsvaerd DK
- Final discussion, questions and answers

## Future role of European scientific associations

### Co-Chairs

*Dominique Duchêne and Malcolm Rowland*

### Objectives

One of the major objectives of EUFEPS is to advance research in the pharmaceutical sciences in Europe. This can be achieved by promoting cooperation between national, regional, and European societies or associations which aim at the advancement of pharmaceutical sciences and by promoting cooperation between and with other pharmaceutical organisations. How to move from the official wish of EUFEPS to reality? How to make European pharmaceutical sciences a partner in the world scientific competition? This will constitute the backbone of our discussions.

### Format

Lectures and discussions

### Target Audience

Representatives of European pharmaceutical sciences societies, scientists, students in pharmaceutical research

### Programme

- Presentation of EUFEPS objectives
- Examples of collaboration with EUFEPS member societies, and other European organisations
- How to collaborate in the future for the international development of European pharmaceutical sciences

*10<sup>th</sup> EUFEPS Conference on*

## **Optimising Drug Development: Getting the dose right**

Jointly organised with the European Center of  
Pharmaceutical Medicine's  
Workshop Series on Frontiers in Drug Development

*Basel Convention Center • December 9-11 • 2002*



EUROPEAN FEDERATION  
FOR PHARMACEUTICAL  
SCIENCES

PO Box 1136, SE-111 81 Stockholm, Sweden  
Phone +46 8 7235000 Fax +46 8 4113217  
Email [secretariat@eufeps.org](mailto:secretariat@eufeps.org)  
Website [www.eufeps.org](http://www.eufeps.org)